bluebird bio, Inc. (NASDAQ:BLUE)‘s stock had its “hold” rating reaffirmed by Jefferies Group LLC in a research note issued on Wednesday.
A number of other analysts also recently weighed in on BLUE. Morgan Stanley reiterated an “equal weight” rating and set a $105.00 price target (up from $91.00) on shares of bluebird bio in a report on Wednesday, June 14th. Standpoint Research reiterated a “reduce” rating and set a $110.00 price target on shares of bluebird bio in a report on Friday, June 16th. BidaskClub raised shares of bluebird bio from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. Wedbush reissued an “outperform” rating and set a $100.00 price objective (down previously from $121.00) on shares of bluebird bio in a research report on Friday, June 23rd. Finally, Cowen and Company reissued a “buy” rating on shares of bluebird bio in a research report on Friday, June 23rd. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company’s stock. bluebird bio has a consensus rating of “Hold” and an average target price of $116.91.
bluebird bio (BLUE) opened at 131.65 on Wednesday. bluebird bio has a 12-month low of $37.05 and a 12-month high of $143.50. The firm’s 50-day moving average price is $123.70 and its 200 day moving average price is $101.61. The company’s market capitalization is $6.00 billion.
bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.66) by ($0.07). bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The business had revenue of $16.70 million for the quarter, compared to analyst estimates of $6.29 million. During the same quarter in the previous year, the business posted ($1.59) earnings per share. The business’s revenue was up 977.4% on a year-over-year basis. On average, analysts expect that bluebird bio will post ($6.85) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2017/10/11/bluebird-bios-blue-hold-rating-reiterated-at-jefferies-group-llc.html.
In other news, Director Daniel Lynch sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $120.00, for a total transaction of $60,000.00. Following the completion of the sale, the director now owns 3,300 shares in the company, valued at approximately $396,000. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider David Davidson sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $92.37, for a total transaction of $277,110.00. Following the sale, the insider now owns 18,977 shares of the company’s stock, valued at approximately $1,752,905.49. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 126,879 shares of company stock valued at $15,401,808. 3.90% of the stock is currently owned by company insiders.
Several hedge funds have recently modified their holdings of BLUE. QS Investors LLC grew its stake in bluebird bio by 70.7% in the 2nd quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 500 shares in the last quarter. Bank of Montreal Can grew its stake in bluebird bio by 118.9% in the 2nd quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after buying an additional 911 shares in the last quarter. Turner Investments LLC purchased a new position in bluebird bio in the 2nd quarter valued at approximately $184,000. SG Americas Securities LLC grew its stake in bluebird bio by 17.9% in the 2nd quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 295 shares in the last quarter. Finally, Fairfield Bush & CO. purchased a new position in bluebird bio in the 2nd quarter valued at approximately $210,000.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.